Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
Company overview

Vicore Pharma: FPI Covid-19

Redeye Research Note timeStamp 2020/07/28

Redeye reiterates its positive stance towards Vicore following the announcement of first Covid-19 patient being dosed in its phase II trial. We currently regard the Covid-19 indication as a bonus in our Base case, with considerable scope for re-valuation if results are proven encouraging. We expect top-line results from the trial already later this year.

The ATTRACT-trial is a randomised, double-blind, placebo-controlled phase II study that will enrol 100 patients to either VP01 (C21) 100 mg twice a day or placebo in a 1:1 manner. The aim of the study is to investigate the safety and efficacy of VP01 (C21) in hospitalised COVID-19 patients who do not require mechanical ventilation. The primary goal is to investigate whether VP01 (C21) can prevent disease progression before the patient is in a critical condition.

As argued in our initaton report, evaluating VP01 in Covid-19 patients makes sense given its known effect of triggering an imbalance in the RAS system. We also favour the study’s design, as the endpoints are objective measures. We believe the results will provide a clear ‘stop or go’ decision for Vicore. In line with the company, we believe top-line results could be presented already later this year.

Ludvig Svensson

Ludvig Svensson

Equity Analyst

Tagged companies
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Terms and conditions - Advisory (Swedish)
  • Terms and conditions - Advisory (English)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2021

You need to be a Redeye member to access this content

Become a member to:

  • Access all our extensive research on 100+ Nordic Tech and Life Science companies
  • Make smarter investment decisions with the guidance of our experienced analysts
  • Receive exciting offers to participate in IPO’s and other transactions

    By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions

    I already have an account and want to sign in